Sign In
MCK.US
id: 539

McKesson Corporation (MCK) $141 MM Investors Settlement

The settlement funds have been distributed to claimants.
$141,000,000
Cash Settlement
N.D. California
Court
18-CV-06525
Case number
10/24/2013
Class period Start
01/25/2017
Class period End
05/10/2023
Claim deadline
McKesson Corporation (MCK) agreed to pay up to $141 million to settle a securities class action lawsuit to avoid further litigation.

The complaint alleged that the Company and its Leaders made false and/or misleading statements and/or failed to disclose that:
  • McKesson and several of its industry peers colluded to fix the price of certain generic drugs;
  • the collusive conduct constituted a violation of federal antitrust laws;
  • consequently, McKesson’s revenues were, in part, the result of illegal conduct and were therefore unsustainable;
  • McKesson lacked effective internal controls over financial reporting.
Case Type
US Securities Class Action
Case Status
Disbursed
Alleged Offence
Other
Suspected Party
Other
Security Type
Stocks
Trade Direction
Long
Filing date
10/25/2018
Plaintiffs
Trust Fund for Operating Engineers
Attorneys
Robbins Geller Rudman & Dowd LLP (San Diego, CA)
Defendants
John H. Hammergren, James Beer
Judge
Hon. Charles R. Breyer
Administrator
Gilardi & Co LLC
Court hearing date
06/02/2023
Exclusion deadline
05/12/2023
Objection deadline
05/12/2023
Trades matching type
FIFO
Disbursement date
11/20/2024

McKesson Corporation

McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, Prescription Technology Solutions (RxTS), Medical...

    Ticker
    MCK.US
    ISIN
    US58155Q1031
    CIK
    0000927653
    Sector
    Healthcare
    Industry
    Medical Distribution
    Country
    USA
    Address
    6555 State Highway 161, Irving, TX, United States, 75039